| Code | 2513C | ||||||||||
| MA number | 16/0006/17-S | ||||||||||
| Product Form: | tbl ent 28x100 mg (blis.PVC/Al) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| Therapeutic Class: | 16 - ANTICOAGULANTIA (FIBRINOLYTICA, ANTIFIBRINOL.) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10a well-established use application |
| MA issued: | 16.01.2017 |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Abrea_75 mg_100 mg_160 mg_06.2023.pdf
|
| PIL: |
PIL_Abrea_75 mg_100 mg_160 mg_06.2023.pdf
|
| Safety feature | Yes |
| Data update: | 25.04.2022 |
